NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it will host a virtual fireside chat with Harry Simeonidis, President & CEO and Spiro Sakiris, CFO at 4:30 p.m. ET on December 11, 2024.

During the event, management will discuss the Company's recent clinical study results, path to FDA 510(k) submission, and offer investors an opportunity to ask questions.

Virtual Fireside Chat Details:
Dates: December 11, 2024
Presentation Time: 4:30 p.m. ET
Registration Link:

A Q&A portion will occur at the end of the call and a link to the recording of the presentation will be available on INBS' Investor Relations website after the event.

About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

For more information, visit:

Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc

Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com